Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by RBC Capital, and Vertex Pharmaceuticals maintained their sector perform rating. The last upgrade for Vertex ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...